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Endothelial cells react to factor Xa and thrombin by proinflammatory responses. It is unclear how these cells respond under physiological
conditions, where the serine proteases factor VIIa, factor Xa and thrombin are all simultaneously generated, as in tissue factor-driven blood
coagulation. We studied the Ca2+ signaling and downstream release of interleukins (ILs), induced by these proteases in monolayers of human
umbilical vein endothelial cells. In single cells, factor Xa, but not factor VIIa, complexed with tissue factor, evoked a greatly delayed, oscillatory
Ca2+ response, which relied on its catalytic activity and resembled that of SLIGRL, a peptide specifically activating the protease-activated receptor
2 (PAR2). Thrombin even at low concentrations evoked a rapid, mostly non-oscillating Ca2+ response through activation of PAR1, which
reinforced the factor Xa response. The additive Ca2+ signals persisted, when factor X and prothrombin were activated in situ, or in the presence of
plasma that was triggered to coagulate with tissue factor. Further, thrombin reinforced the factor Xa-induced production of IL-8, but not of IL-6.
Both interleukins were produced in the presence of coagulating plasma. In conclusion, under coagulant conditions, factor Xa and thrombin appear
to contribute in different and additive ways to the Ca2+-mobilizing and proinflammatory reactions of endothelial cells. These data provide first
evidence that these serine proteases trigger distinct signaling modules in endothelium that is activated by plasma coagulation.
© 2006 Elsevier B.V. All rights reserved.Keywords: Calcium; Coagulation; Endothelial cells; Factor Xa; Thrombin1. Introduction
Coagulation, i.e., formation of fibrin, is initiated by complex
formation of tissue factor with the protease factor VIIa and is
propagated by proteolytic activity of two other proteases, factor
Xa and thrombin [1]. Factor X is activated by the tenase
complex in the presence of phospholipids to form factor Xa.
The latter forms with cofactor Va and phospholipids the
prothrombinase complex, which then cleaves prothrombin into
thrombin. Activated cells are considered to provide the
procoagulant phospholipid surface. There is broad evidence⁎ Corresponding author. Lab. of Histology, Neuroanatomy and Neuropa-
thology, Université Libre de Bruxelles, 1070 Bruxelles, Belgium. Tel.: +32 2
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doi:10.1016/j.bbamcr.2006.04.010that the coagulation proteases, factor VIIa, factor Xa and
thrombin, once activated, also evoke a variety of responses in
cells from the vascular system. For instance, in endothelial and
other cells, both proliferative and acute inflammatory effects of
the activated coagulation factors have been described [2–4]. In
endothelial cells, the proinflammatory response induced by
factor Xa consists of cytokine production and expression of
adhesion molecules [5,6].
Endothelial cells contain at their surface a number of
protease-activated receptors (PARs), which, following cleav-
age, can couple to signaling G proteins. There is general
agreement that thrombin activates Gq-coupled PAR1 and PAR4
on endothelial cells [7–9], but by which receptors factor Xa
signals are still unclear. Earlier, it was thought that factor Xa
acts through the elusive effector cell protease receptor 1 (EPR1)
[10,11], but the existence of this receptor is now questionable
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PAR2 acts as receptor for factor Xa [13]. However, expression
studies with cell lines indicate that factor Xa can also signal via
PAR1 and PAR4, while knockout mouse models suggest that
PAR1 along with PAR2 contributes to factor Xa-induced
activation of endothelial cells [9]. Recent evidence also suggests
co-activity of the coagulation proteases, e.g., the ternary
complex of tissue factor and factor VIIa and factor Xa is
considered to be more potent than its separate components on
cellular activation, when formed on the surface of tissue factor-
expressing cells [14,15].
In vivo, endothelial cells subjected to conditions of
hemostasis or thrombosis are faced with the combination of
all coagulation proteases and not with single factors. However,
only very little is known of the endothelial responses under
conditions of coagulation, when all these proteases are
simultaneously generated. In this paper, we present single cell
data, showing that factor Xa and thrombin evoke distinct and
additive Ca2+ responses in confluent monolayers of native
endothelial cells. These different Ca2+ responses were accom-
panied by additive effects on cytokine release and were
maintained in the presence of coagulating plasma. The results
thus suggest that different sets of receptors and signaling routes
are involved in the endothelial reactions to factor Xa and
thrombin generated during coagulation.Fig. 1. Characteristics of factor Xa-induced Ca2+ responses in HUVEC. Confluent m
320 nM), thrombin (1–40 nM) or SLIGRL (10 μM) in HEPES buffer pH 7.4 contain
FXa. Shown are traces of a representative cell with oscillations (black), and averaged t
104 cells) or 4 nM thrombin: no Ca2+ response (white), oscillating Ca2+ response (grey
increase after stimulation with thrombin, factor Xa or SLIGRL (mean±S.E.M., 90–2. Materials and methods
2.1. Materials
Hirudin was obtained from BASF (Ludwigshafen, Germany). Fura-2 and
Fura-red acetoxymethyl esters were from Molecular Probes (Leiden, The
Netherlands); annexin A5 was from Nexins Research (Hoeven, The Nether-
lands); SLIGRL and SFLLRN from Bachem (Bubendorf, Switzerland).
Chromogenic factor Xa substrate (Pefachrome Xa) was from Pentapharm
(Basel, Switzerland), and thrombin-cleavable substrate (S2238) from KabiVi-
trum (Stockholm, Sweden).
Recombinant human tissue factor containing the membrane-spanning
domain (Innovin) was from Dade Behring (Marburg, Germany). Soluble, 219
residues tissue factor was a generous gift from Henogen (Gosselies, Belgium).
Human prothrombin (factor II) and bovine factor Va were purified, as described
before [16]; human thrombin was from Sigma (St. Louis, MO, USA). Factor Xa
was purified from bovine and human plasma as described [17] and activated
with Russell's viper venom [18]. Factor Xa activity was measured by the ability
to hydrolyse Pefachrome Xa; purity was controlled by SDS-PAGE and staining
with Coomassie brilliant blue. Modified bovine factor Xa, lacking the γ-
carboxyglutamic acid (Gla) residues (factor Xa-gla), was a kind gift from Drs. J.
Rosing and G. Tans (Dept. of Biochemistry, University of Maastricht) and was
prepared as described elsewhere [19]. The concentration of factor Xa-gla was
calculated from this activity toward Pefachrome Xa, assuming identical
amidolytic activity to factor Xa. Active site-inhibited factor Xa was obtained
by incubation of native factor Xa with dansyl-glutamylglycyl-L-arginine
(DEGR) chloromethyl ketone (Calbiochem, La Jolla CA, USA), as described
[20]. Antithrombin was obtained from bovine plasma and purified to
homogeneity as described by others [21]. Other materials were obtained from
Sigma (St. Louis, MO, USA).onolayers of Fura-2-loaded HUVEC were stimulated with factor Xa (FXa, 4–
ing 1.8 mM CaCl2 at 37 °C. (A, B) Changes in [Ca
2+]i in response to 4 or 80 nM
races of 27 cells (grey). (C) Fractions of cells responding to 4–320 nM FXa (19–
), or non-oscillating prolonged response (black). (D) Lagtime before first [Ca2+]i
104 cells). Data are from at least three independent experiments.
Fig. 2. Additional Ca2+ responses with factor Xa and thrombin. Fura-2-loaded
HUVEC were stimulated as described for Fig. 1. (A, B) Traces of [Ca2+]i upon
stimulation with FXa (40 nM) and thrombin (10 nM), as indicated. Shown are
traces of a single cell (black) and averaged traces of 25 cells (grey). Data are
representative for 3 or more independent experiments.
862 V. Daubie et al. / Biochimica et Biophysica Acta 1763 (2006) 860–8692.2. Endothelial cell culturing and stimulation
HUVEC were isolated from fresh umbilical cords by treatment with
collagenase type I (Sigma) and were grown in RPMI 1640 medium as described
[5]. Cells of passages 1 through 4 were seeded on coverslips or culture plates at a
density of 5×104/cm2 and grown to confluency. For real-time [Ca2+]i
measurements, cells were grown on gelatine-coated glass coverslips [22].
Briefly, coverslips were activated with 0.5% (w/v) glutaraldehyde in phosphate-
buffered saline (PBS) and then coated with 1% (w/v) gelatine (Difco, Detroit,
USA) in PBS. After a wash step, the gelatine on coverslip was treated with 0.5%
glutaraldehyde in PBS for 30 min, washed twice, and HUVEC were seeded. The
endothelial cells were cultured for 2–3 days to confluence in air containing 5%
CO2 at 37 °C. For interleukin and coagulation measurements, the HUVEC were
grown on fibronectin-coated 96-well flat-bottom tissue culture plates in RPMI
1640 medium [5]. Cells on coverslips of wells were stimulated with indicated
concentrations of factor Xa, thrombin or other (ant)agonists at 37 °C. In some
experiments, the cells were incubated with bacterial-free human plasma and then
stimulated with CaCl2 and tissue factor.
2.3. Measurement of cytosolic Ca2+ concentration
Confluent monolayers of HUVEC on coverslip were loaded with
fluorescent Ca2+ probe, basically as described [23]. The cells were washed
twice with HEPES buffer pH 7.4, consisting of 150 mM NaCl, 5 mM KCl,
1 mM MgCl2, 10 mM HEPES, 5 mM glucose, 4 mM glutamine, 0.25% (w/v)
bovine serum albumin (BSA) and 1.8 mM CaCl2. For most experiments, the
cells were then loaded with 1 μM Fura-2 acetoxymethyl ester in HEPES
buffer containing 1% BSA for 30 min at 37 °C. For experiments with
coagulating plasma, the cells were loaded with 10 μM Fura-red acetox-
ymethyl ester in the same buffer for 20 min at 37 °C. After loading with
fluorescent probe, the cells were incubated with HEPES buffer for 15 min to
allow complete de-esterification of the dye.
Coverslips with loaded cells were mounted in a 1 ml thermostated (37 °C)
open chamber placed on a Nikon Diaphot or Olympus inverted microscope.
Factor Xa, thrombin and other agonists were added to the chamber in volumes of
100–200 μl in HEPES buffer pH 7.4. All concentrations given are final.
Changes in Fura-2 fluorescence in individual cells were measured by calibrated
ratio fluorometry at 340 and 380-nm excitation, using a camera-based Quanticell
video imaging system (Visitech, Sunderland, UK) [24]. Changes in Fura-red
fluorescence were measured by ratio fluorometry using a camera-based
TillVision imaging system (Till Photonics, Gräfelfing, Germany). Fluorescence
at excitation at 463 and 472 nm was detected at 660 nm, and ratio values were
obtained. In the latter case, no calibration was applied, since the clot formation
interfered with the fluorescence detection.
2.4. Coagulation measurements
Blood, drawn from healthy donors, was collected in 1/10 volume of 129 mM
trisodium citrate. Platelet-poor plasma (PPP) was prepared by centrifugation
[25]. Generation of factor Xa and clotting times were measured as described
[16]. Thrombin generation was measured in a continuous assay, as described
[25].
2.5. Measurement of interleukins
To measure interleukins (IL), supernatants were harvested from HUVEC
on culture platelet at the end of incubation periods. Cytokine levels were
determined using an earlier published sandwich ELISA for IL-6 and IL-
8 [5]. The lower detection limit of the immunoassays was 10 pg/ml.
Expression of adhesion molecules on activated HUVEC was detected, as
described [5].
2.6. Statistical analysis
Data are shown as means±S.E.M. Statistical significance was determined
using ANOVA and Bonferoni post-hoc analysis using Prism 4 software (Graph
Pad Inc.). Data were considered to be statistically significant at P<0.05.3. Results
3.1. Factor Xa and thrombin evoke distinct Ca2+ responses in
single endothelial cells
In populations of suspended endothelial cells, purified
factor Xa causes phospholipase C activation [9,13] and a
small, transient Ca2+ mobilization [26]. We aimed to study
the factor Xa-induced Ca2+ signaling at more physiological
conditions, by using confluent monolayers of adherent human
endothelial cells. Early passage HUVEC, grown to con-
fluency on gelatine-coated coverslips, were loaded with the
fluorescence ratio probe Fura-2, and changes in fluorescence
were monitored per individual cell by microscopic fluores-
cence video imaging [23]. In the majority of cells (61%) in
monolayer, addition of >4 nM bovine factor Xa elicited a
strongly delayed, oscillatory change in [Ca2+]i (Fig. 1A).
Other responsive cells showed a delayed, single transient
increase in [Ca2+]i. At a concentration of 80 nM factor Xa,
the oscillation pattern was often regular in appearance (57/100
cells, Fig. 1B).
Dose–response curves indicated that the average spiking
frequency increased from 0.10 to 0.27 and 0.35 min−1 at 5,
40 and 80 nM factor Xa, respectively. The fraction of cells
with oscillations decreased from 61% to 34%, when factor
Xa was given above physiological concentrations of 160–
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concentrations, the cell fraction with oscillatory responses
again increased to 72%, when CaCl2 was omitted from the
incubation medium.
Remarkably, all factor Xa-stimulated cells showed a long
lagtime of several minutes before onset of the Ca2+ response
which then continued for a long time (Fig. 1D). Although
quite variable from cell to cell, the averaged lagtime reduced
with the factor Xa concentration, reaching a plateau level of
150 s at >40 nM factor Xa. Because the Ca2+ responses of
individual HUVEC were asynchronous, the averaged response
of all cells in the monolayer appeared as a delayed, transient
[Ca2+]i increase. In three experiments, the averaged maximal
increase at 40 nM factor Xa amounted to 95±20 nM [Ca2+]i.
Bovine and human factor Xa caused similar Ca2+ response
patterns.
Factor Xa-induced activation of endothelial phospholipase
C is supposed to be mediated by PAR2 and possibly PAR1,
while thrombin can signal via PAR1 and PAR4 [9]. This
suggests that factor Xa and thrombin can have partially
overlapping effects on Ca2+ signaling. We found that, in
HUVEC, thrombin (1–40 nM) caused a quite different type
of Ca2+ response, consisting of rapid, broad Ca2+ transient
(Fig. 2). Only a minority of about 10% of the cells showed
signs of multiple Ca2+ oscillations, in this case with a high
spiking frequency of 1.8 min−1 (Fig. 1C). In marked contrast
to factor Xa, all cells responded to low and high doses of
thrombin by an almost immediate increase in [Ca2+]i (Fig.Fig. 3. Similarity of Ca2+ responses with factor Xa and PAR2 agonist SLIGRL. Fura-
indicated. Subsequently, the cells were stimulated with FXa (40 nM), SLIGRL (10 μM
representative, single cell (black and dashed lines) and averaged traces (grey). Panels
(B) Continuation of panel A; stimulation of the same cells with SLIGRL after 20 m
SLIGRL and thrombin.1D). At 4 nM thrombin, the lagtime of 126/132 cells was 10–
15 s, which was the time of diffusion of the agonist to the
cells. SFLLRN is able to activate PAR1 and PAR2 but with
different affinities (PAR-1 being 16 times more affine than
PAR2) as shown in 2001 by Maryanoff et al. [27]. Like
thrombin, the PAR1 agonist SFLLRN caused an immediate
transient Ca2+ signal (not shown). Thrombin also evoked an
immediate, transient [Ca2+]i increase when applied after factor
Xa (Fig. 2A). On the other hand, after stimulation with
thrombin, most cells still responded to factor Xa by a delayed
Ca2+ signal (Fig. 2B).
Similarly to factor Xa, the specific PAR2 agonist SLIGRL,
at a high dose of 10 μM, evoked a greatly delayed Ca2+
response in most HUVEC (Fig. 1D). Also in this case,
responses were oscillatory in 68% (50/73) of the cells. Several
other observations pointed to high similarity of the factor Xa-
and SLIGRL-induced responses. For instance, in some cells,
factor Xa (Fig. 3A) and SLIGRL (Fig. 3C) evoked a multi-
spike [Ca2+]i transient that was followed by single-spike
oscillations. Second, addition of SLIGRL to cells which were
preincubated with a moderate dose of factor Xa did not alter the
oscillating Ca2+ response pattern (Fig. 3B). Conversely, factor
Xa did not modulate the response to SLIGRL (Fig. 3C).
Further, in cells preactivated with a high dose of factor Xa,
SLIGRL caused only little Ca2+ spiking, while thrombin
induced a high [Ca2+]i increase (Fig. 3D). Together, this
indicates that activated PAR2 plays a major if not sole role in
the factor Xa-induced Ca2+ response of HUVEC.2-loaded HUVEC were preincubated with FXa (40–300 nM) for 20 min, where
) or thrombin (4 nM), and Ca2+ responses were monitored. Shown are traces of a
give typical, oscillating Ca2+ responses observed with FXa (A) or SLIGRL (C).
in. (D) Cells pretreated with FXa (300 nM) for 20 min were stimulated with
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activity and is not enhanced by factor VIIa
The structural requirements of factor Xa for causing the
oscillatory changes in Ca2+ were investigated. Treatment of
factor Xa with antithrombin – which is a physiological
inhibitor of both factor Xa and thrombin – completely
abolished the Ca2+ signal in HUVEC (Fig. 4A). In contrast,
treatment with hirudin – which only inhibits thrombin
activity – did not influence the factor Xa-induced Ca2+
response. A modified form of factor Xa was tested, lacking
the Gla residues responsible for Ca2+-dependent binding,
e.g., to phospholipids [1]. While this form did not evoke a
Ca2+ signal, intriguingly, it caused immediate oscillations
when replaced by unmodified factor Xa (Fig. 4B). However,
the factor Xa-induced activation did not rely on binding to
procoagulant phospholipids, since it was not influenced by
phosphatidylserine-binding annexin A5. To investigate the
importance of the proteolytic activity, factor Xa was treated
with DEGR-chloromethyl ketone, which inactivates its
catalytic site. The loss of protease activity was verified by
amidolytic measurement. Active site-inhibited factor Xa was
non-responsive to HUVEC, but normal Ca2+ responses
occurred when it was replaced by unmodified factor Xa
(Fig. 4C). Further, post-addition of DEGR-chloromethyl
ketone immediately blocked all factor Xa effects (Fig. 4D).Fig. 4. Requirement of catalytic activity and Gla domain for factor Xa-induced Ca2+ re
for Fig. 1. (A) Cells were treated with a mixture of 40 nM FXa and 160 nM antithromb
(B) Cells were treated with 80 nM FXa lacking Gla residues (FXa-gla), which was late
were treated with 80 nM active site-inhibited FXa (DEGR-FXa), which was later repla
after which 80 nM FXa and 10 μMDEGR-chloromethyl ketone were added. Represe
experiments) (grey).In conclusion, these results indicate that the continuous
presence of the active (proteolytic) site and Gla domains are
needed for factor Xa to induce Ca2+ oscillations, likely via
proteolytic receptor cleavage.
In transfected cells where membrane-bound tissue factor
and factor VIIa are co-localized on the cell surface, it has
been described that the tissue factor–factor VIIa complex
facilitates the factor Xa-dependent signaling [14]. We used
two forms of tissue factor to study its Ca2+-mobilizing
effect in endothelial cells: a recombinant soluble tissue
factor fragment, which binds to factor VII(a) with low
affinity, and recombinant longer chain tissue factor
(Innovin), containing the membrane-spanning domain with
a much higher affinity for factor VII(a). First, the doses of
soluble (100 nM) and of long-chain (10 pM) tissue factor
were established that gave clotting times in recalcified
phospholipid-containing plasma of about 120 s. The
HUVEC were then treated at these tissue factor concentra-
tions in the presence of equimolar factor VIIa. Neither of
the tissue factor–factor VIIa complexes was able to cause a
significant Ca2+ response (Fig. 5A).
Subsequently, we determined the effect of combined
addition of (soluble or membrane-bound) tissue factor, factor
VIIa and factor Xa. This resulted in Ca2+ responses that were
similar in magnitude (Fig. 5B) and shape (not shown, but see
below) as the responses evoked by factor Xa alone. In a nextsponses. Fura-2-loaded HUVECwere used for Ca2+ measurements, as described
in (AT), which was later replaced by a mixture of 40 nM FXa and 5 U/ml hirudin.
r replaced by 80 nM FXa, after which 15 μg/ml annexin A5 was added. (C) Cells
ced by 80 nM FXa. (D) Cells were preactivated with low 10 nM FXa for 20 min,
ntative traces are shown of a single cell (black) and averaged of 15–25 cells (2–3
Fig. 5. Additional effects of in situ generated factor Xa and thrombin on Ca2+ signaling. (A) Averaged [Ca2+]i trace of Fura-2-loaded HUVEC incubated with 100 nM
soluble tissue factor (sTF), 100 nM factor VIIa (FVIIa), followed by 10 nM thrombin. (B) Maximal increases in [Ca2+]i in HUVEC are given induced by the indicated
combinations of 40 nM FXa or FX, 100 nM FVIIa, 100 nM sTF, and 10 nM thrombin; alternatively [Ca2+]i increases with 10 pM full-length TF in combination with 10
pM FVIIa. Data are from averaged traces (mean values±S.E.M., n=3–9 experiments). (C, D) Calcium responses due to in situ activation of FX and prothrombin (FII).
HUVEC were incubated with 100 nM sTF, 100 nM FVIIa and 40 nM FX. Subsequently, thrombin generation was induced with 0.1 nM FVa and 10 nM FII. Traces are
given of a representative cell (black) and averaged of 32 cells (grey). (D) Fractions of cells responding to in situ FX and FII activation: no Ca2+ response (white),
oscillating Ca2+ response (grey), or non-oscillating prolonged response (black).
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a mixture of soluble tissue factor, factor VIIa and factor X.
Parallel factor Xa generation measurements indicated that, at
the cofactor concentrations used (see Fig. 5B), the conversion
of factor X into Xa was complete for 91% in 30 s. Similarly
to factor Xa itself, the mixtures provoked delayed, oscillatory
Ca2+ responses (Fig. 5C), which on average had a mean size
of 110–123 nM, i.e., similar to the mean response of added
factor Xa (Fig. 5B). Importantly, subsequent addition of factor
Va and prothrombin (factor II) to provoke thrombin (factor
IIa) generation resulted in a second, much higher Ca2+
response in all cells. Parallel measurements of thrombin
generation indicated that, in 60 s, 99% of all prothrombin was
converted into thrombin.
Similarly as observed with factor Xa or thrombin alone, a
much higher fraction of the cells displayed oscillatory changes
in [Ca2+]i during the period of in situ factor X activation than
during the next period of prothrombin activation (Fig. 5D).
Together, these results thus show that HUVEC monolayers
respond in a similarly way to in situ formed factor Xa and
thrombin as to addition of the preactivated factors. Furthermore,
the factor Xa-induced response is not enhanced by tissue factor
and factor VIIa.3.3. Factor Xa and thrombin differently evoke cytokine release
in endothelial cells
The distinct factor Xa- and thrombin-induced Ca2+
responses in endothelial monolayers point to additive effects
of these coagulation proteases on cell activation. This was
further investigated by measuring downstream activation events
[28], i.e., expression of the proinflammatory cytokines IL-6 and
IL-8 [5]. TNFα was used as a positive control, giving high
levels of interleukin production. In the HUVEC monolayers,
factor Xa but not thrombin evoked a two-fold increase in IL-6
production (Fig. 6A). On the other hand, factor Xa and
thrombin potently induced IL-8 production; thrombin further
increased the effect of factor Xa (Fig. 6B). Thus, both proteases
appear to be involved in IL-8 production, but factor Xa in IL-6
production.
3.4. Endothelial cells treated with coagulating plasma respond
to factor Xa and thrombin
The physiological significance of these findings was
assessed by subjecting HUVEC to coagulating human plasma.
Because plasma is highly fluorescent at the Fura-2 340/380-nm
Fig. 6. Variable effects of factor Xa and thrombin on interleukin production by HUVEC. HUVEC in culture plates were treated with control vehicle, thrombin
(1–100 nM), factor Xa (40 nM) or tumor necrosis factor-α (TNF, 20 ng/ml). Supernatants were collected from cells after 20 h of treatment, and assayed for IL-6
and IL-8 production. Data are mean values±S.E.M. of 4 or more experiments. **P<0.05 compared to control.
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with HUVEC that were loaded with the longer wavelength
probe Fura-red, which also shows a small but significant shift in
fluorescence ratio upon Ca2+ binding. Calibrated control
experiments with Fura-red-loaded HUVEC indicated that factor
Xa in the presence of HEPES buffer caused the normal
oscillating Ca2+ responses (250-nM peak levels), although in
total, only 58% of the cells were responsive (data not shown),
likely due to the high concentration of Fura-red needed for
fluorescence detection.
The Fura-red-loaded HUVEC were incubated with
plasma that was triggered to coagulate with soluble tissue
factor and CaCl2. Control measurements of factor Xa and
thrombin generation in plasma indicated that 0.5 μM
soluble tissue factor/CaCl2 induced after 1 min levels of
250 nM and 9 nM, and after 2 min levels of 150 nM and
9 nM of thrombin and factor Xa, respectively. In the
presence of 100 U/ml hirudin, thrombin generation was
abolished, while factor Xa still peaked at about 9 nM (see
also [29]). Tissue factor addition evoked in many cells an
initial transient Ca2+ signal, which was followed by one or
more Ca2+ oscillations (Fig. 7A). Importantly, in plasma
preincubated with hirudin to block the generation of
thrombin but not factor Xa, all responding cells showed
oscillatory [Ca2+]i changes (Fig. 7A, B). Again, only part
of the Fura-red-loaded cells was responsive, with about
45% showing no [Ca2+]i increase.Measurements of cytokine production indicated that
soluble tissue factor dose-dependently increased the produc-
tion of both IL-6 and IL-8 (Fig. 8). Taken together, these
results indicate that the HUVEC in contact with coagulating
plasma responded to both generated factor Xa and thrombin
by specific patterns of Ca2+ responses and interleukin
release.
4. Discussion
The present results show that factor Xa, similarly as the
PAR2-specific agonist SLIGRL, causes greatly delayed,
oscillatory Ca2+ responses in HUVEC with lag times of
two or more minutes, depending on the factor Xa
concentration. Such delayed, oscillatory responses have not
yet been described for endothelial cells triggered with
coagulation factors, and point to a unique receptor-
activating signaling pathway. It has not yet been identified,
likely because others have concentrated on measurements in
suspensions of non-adherent endothelial cells, e.g., deter-
mining factor Xa-induced phospholipase C activity [9,13,26]
and/or Ca2+ signaling [7,26]. It is also conceivable that
such cells are already in an activated state by being in
suspension. Typically, the delayed responses in endothelium
are also distinct from the factor VIIa- and factor Xa-
induced oscillatory Ca2+ responses in Madin-Darby canine
kidney cells, which present a very short delay time and are
Fig. 7. Effects of factor Xa and thrombin generation in plasma on Ca2+ signaling in HUVEC. (A) Fura-red-loaded HUVEC were incubated with human plasma, which
was triggered with 0.15 μM soluble tissue factor (sTF) and 16.6 mM CaCl2. Plasma was preincubated with 100 U/ml hirudin to block thrombin activity, where
indicated. Fluorescence ratio traces of Ca2+ responses given of single cells and populations of cells (n=10) are representative for 3–4 experiments. (B) Fractions of
cells responding sTF: no Ca2+ response (white), oscillating Ca2+ response (grey), or non-oscillating prolonged response (black). Control runs showed that hirudin alone
did not induce Ca2+ signaling (not shown).
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or PAR2 [30]. The mechanism underlying the delayed
response in HUVEC is unclear. However, a clue comes
from the observation that pretreatment with a Gla domain-
lacking factor Xa greatly shortens this lag time. This may
imply that factor Xa-induced activation occurs after slow
binding to the receptor (PAR2) and/or via slow transactiva-
tion of another receptor (see below). However, other
explanations like delayed intracellular reactions cannot be
ruled out.
After recognition that the gene of the elusive factor Xa
receptor, EPR1 [10], in fact encodes for a protein regulating
apoptosis [12], it has been a matter of debate which
receptor(s) mediate factor Xa-induced effects on vascular
cells. In agreement with previous data of factor Xa-induced
cytokine production [5], we have not found evidence for
involvement of EPR1 in the Ca2+ responses of HUVEC.
For instance, EPR1-derived peptides, designed to interact
with factor Xa, were unable to influence the factor Xa
responses (N. Senden, unpublished data). Recent findings
with knockout mice imply that in murine endothelial cells
both PAR1 and PAR2 can contribute to factor Xa effects
[9]. The same conclusion was drawn for vascular cells from
receptor desensitization studies with thrombin and peptide
agonists of PAR1 and PAR2 [31]. In HeLa cells, it was
concluded that factor Xa similarly to thrombin can elicit
NF-kappa B activation but in a delayed way [32]. Our
findings with human endothelial cells indicate that delayedsignaling is a characteristic effect of factor Xa and the
PAR2-specific peptide agonist SLIGRL. Since this peptide
does not enhance the Ca2+ signaling activity of factor Xa, it
appears that PAR2 acts as the main functional factor Xa
receptor in HUVEC. Another typical observation is that
tissue factor and factor VIIa do not further enhance the Ca2+
signal with factor Xa. This indicates that ternary complex
formation of factor Xa with tissue factor and factor VIIa
[14] is not a major determinant of factor Xa-induced
signaling in the HUVEC. Others have suggested that
endothelial PAR2 may be activated directly by tissue
factor/factor VIIa and indirectly by tissue factor/factor VIIa
generated factor Xa [13]. The present Ca2+ signaling
patterns indicate that in resting HUVEC the latter pathway
is by far predominant. The slow kinetics of the Ca2+
responses with factor Xa or SLIGRL in this respect suggest
that, if transactivation occurs, factor Xa-activated PAR2
signals to activate and cleave PAR1, rather than the other
way around as previously suggested [8].
The present data add well to earlier work showing that
exposure of HUVEC to factor Xa stimulates the production
of proinflammatory cytokines including IL-6 and IL-8, and
de novo expression of adhesion molecules such as E-
selectin, intercellular adhesion molecule-1 (ICAM-1), and
vascular cell adhesion molecule-1 (VCAM-1) [5,6]. Our
work is also in accordance with the work on (micro)vascular
endothelial cells, also producing IL-6 and IL-8 in response
to PAR2 activation by tryptase or peptides [31,33]. A novel
Fig. 8. Effect of coagulating plasma on interleukin production by HUVEC.
HUVEC in culture plates were incubated with HEPES buffer or with 100 μl
recalcified plasma in the absence (control) or presence of 0.15–0.8 μM soluble
tissue factor (sTF). After 20 h, supernatants were collected and assayed for IL-6
and IL-8. Data are mean values±S.E.M. (n=16); **P<0.05 compared to
control plasma.
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evokes IL-6 production. As far as thrombin is concerned,
Weinstein et al. [34] have recently discovered that purified
thrombin can be contaminated, which need to cautiously
interpret results. More specifically, they elegantly showed
that recombinant human thrombin did not induce IL-6
release in microglial cells although purified thrombin above
3 U/ml did. In our study, we used a maximum of 10 U/ml
(=100 nM) of thrombin not triggering IL-6 release in
HUVEC (Fig. 6A) experiments allowing to reasonably
discard any thrombin impurity effect. The literature provides
indirect support that the factor Xa-inhibiting antithrombin
was found to efficiently block IL-6 production in stimulated
HUVEC [35]. Together, this indicates that IL-6 formation
evoked by coagulating plasma is caused by the generated
factor Xa rather than by thrombin. The data show that factor
Xa triggers a relatively prolonged series of Ca2+ oscillations.
Others have proposed that such long-term oscillations have a
function in the Ca2+-dependent activation of transcription
factors [36]. Since IL-6 gene expression has recently been
associated with calcineurin activity [27], such a mechanismmight be triggered by factor Xa, but we do not yet have
direct evidence for this.
Another interesting recent observation is that factor Xa-
induced IL-8 production in HUVEC is sensitive to PAR1
antagonism [6]. Our results, combined with Weinstein's [34]
and Ludeman's results [37], suggested that IL-8 is the product
of PAR-1 signalization and IL-6 the product of PAR2. Indeed,
thrombin by being the major ligand for PAR-1 and not PAR2
induces IL-8 response but not IL-6 response. On the contrary
FXa is ligand for both PAR-1 and 2 and induce both IL-6 and
8 responses.
In summary, we provide first evidence that under coagulant
conditions, factor Xa and thrombin contribute in different and
additive ways to the Ca2+-mobilizing and proinflammatory
reactions of endothelial cells. These data are illustrative for the
interactions between the inflammatory and coagulation path-
ways. They further show that serine proteases, when simulta-
neously generated in plasma, trigger distinct signaling modules
in endothelium, i.e., cells that are naturally exposed to plasma.
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